['multiple myeloma']
['jnj-54767414 (daratumumab)', 'bortezomib', 'dexamethasone']

        Inclusion Criteria:

          -  Participants proven to have symptomatic (having symptoms) multiple myeloma (MM)
             according the International Myeloma Working Group (IMWG) diagnostic criteria

          -  Participant must have documented MM as defined by following criteria: Monoclonal
             plasma cells in the bone marrow 10 percent (%), or presence of a biopsy-proven
             plasmacytoma at some point in their disease history, disease measurements: a) Serum
             M-protein greater than or equal to (>=) 1 gram per deciliter (g/dL) (>=10 gram per
             liter [g/L]) b) Serum immunoglobulin A [IgA] M-protein >= 0.5 g/dL); c) Urine
             M-protein >=200 milligram per 24 hour (mg/24 h); d) Serum immunoglobulin free light
             chain >=10 mg/dL and abnormal serum immunoglobulin kappa lambda free light chain ratio

          -  Participant must have received at least 1 prior line of therapy for MM

          -  Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status
             score of 0 or 1

          -  Participant must have achieved a response (partial response [PR] or better based on
             investigator's determination of response by the IMWG criteria) to at least 1 prior
             regimen

        Exclusion Criteria:

          -  Participant has received daratumumab or other anti-cluster of differentiation 38
             (anti-CD38) therapies previously

          -  Is refractory to bortezomib or another PI, like ixazomib and carfilzomib (had
             progression of disease while receiving bortezomib therapy or within 60 days of ending
             bortezomib therapy or another PI therapy, like ixazomib and carfilzomib

          -  Is intolerant to bortezomib (ie, discontinued due to any adverse event while on
             bortezomib treatment)

          -  Has received anti-myeloma treatment within 2 weeks or 5 pharmacokinetic half-lives of
             the treatment, whichever is longer, before the date of daratumumab first
             administration. The only exception is emergency use of a short course of
             corticosteroids (equivalent of dexamethasone 40 milligram per day [mg/day] for a
             maximum of 4 days) before treatment. A list of anti-myeloma treatments with the
             corresponding pharmacokinetic half-lives is provided in the Site Investigational
             Product Procedures Manual (IPPM)

          -  Has a history of malignancy (other than multiple myeloma) within 3 years before the
             date of daratumumab first administration

          -  Has any concurrent medical condition or disease (eg, active systemic infection,
             pulmonary impairment) that is likely to interfere with study procedures
      